key: cord-0982450-ttfuk0x1 authors: Bowring, Mary G; Wang, Zitong; Xu, Yizhen; Betz, Joshua; Muschelli, John; Garibaldi, Brian T; Zeger, Scott L title: Outcome Stratified Analysis of Biomarker Trajectories for Patients With SARS-CoV-2 Infection date: 2021-05-12 journal: Am J Epidemiol DOI: 10.1093/aje/kwab138 sha: 55cb8233c4e06d4e5c794d6113ab142292eeea98 doc_id: 982450 cord_uid: ttfuk0x1 Longitudinal trajectories of vital signs and biomarkers during admission remain poorly characterized for COVID-19 patients despite their potential to provide critical insights about disease progression. We studied 1884 patients with SARS-CoV2 infection from 3/4/2020-6/25/2020 within one Maryland hospital system and used a retrospective longitudinal framework with linear mixed-effects models to investigate relevant biomarker trajectories leading up to three critical outcomes: mechanical ventilation, discharge, and death. Trajectories of four vital signs (respiratory rate, SpO(2)/FiO(2), pulse, and temperature) and four lab values (C-reactive protein (CRP), absolute lymphocyte count (ALC), estimated glomerular filtration rate (eGFR), and D-dimer) clearly distinguished the trajectories of COVID-19 patients. Prior to any ventilation, log-CRP, log-ALC, respiratory rate, and SpO(2)/FiO(2) trajectories diverge approximately 8-10 days before discharge or death. Following ventilation, log-CRP, log-ALC, respiratory rate, SpO(2)/FiO(2), and eGFR trajectories again diverge 10-20 days prior to death or discharge. Trajectories improved until discharge and remained unchanged or worsened until death. Our approach characterizes the distribution of biomarker trajectories leading up to competing outcomes of discharge versus death. Moving forward, this model can contribute to quantifying the joint probability of future biomarkers and outcomes provided clinical data up to a given moment. In this paper, we propose a linear mixed-effects model to retrospectively study individual biomarker trajectories preceding the key clinical events of initiation of mechanical ventilation, discharge, and death. 8 We use a longitudinal case-control design and outcome-specific strata to describe population and individual biomarker trajectories preceding clinical events to better understand how biomarkers change over time relative to clinical milestones. Readmissions are excluded as data represent the initial episode of care for each patient. Data in JH-CROWN include demographics, medical history, comorbid conditions, symptoms, vital signs, respiratory events, medications, and laboratory results. We studied 1884 patients who died during admission or were discharged prior to data extraction on 6/25/2020 with at least one biomarker value reported during admission. Some patients were included in prior descriptions of the cohort. 4 Ninety-nine patients in the hospital at the time of data extraction were excluded. 4 Elevated pulse is a marker of sepsis and may be associated with worse mortality in sepsis as well as in COVID-19. 10 Patients with pre-existing kidney disease are at higher risk of death from COVID-19. 11 Acute kidney injury is also a risk factor for poor outcomes. 12 D-dimer is associated with severe COVID-19 and has been linked to mortality from COVID-19. 13 Laboratory values reported with ">" or "<" (4.0% of values) were changed to reflect the limit of quantification. For example, if D-dimer was reported as <0.19, 0.19 was used. We calculated daily means for each biomarker. We aimed to characterize population-average and patient-specific biomarker trajectories leading up to major clinical outcomes. For each patient, we treated the day of their outcome as day 0 and studied repeated biomarker measures over previous time from their admission until day 0. Previous time from admission to day 0 will be designated as . If a patient was admitted for COVID-19 20 days before their outcome, we considered admission to be day -20. This approach aligned patient trajectories proximal to event time rather than admission time and allowed us to characterize trajectories immediately preceding major clinical outcomes. We fit two linear mixed-effects models for each biomarker. Let be the jth biomarker value for patient i measured at day from the day of admission for which = 0. Denote baseline predictor variables as and major clinical events as . Consider two possible events after admission denoted by (1) and (2) where (1) = 0, 1, 2 indicates whether the patient was discharged, died, or mechanically ventilated. When (1) = 2, then (2) ∈ {0, 1} indicating whether the person who required ventilation was eventually discharged or died. The 5 clinical outcome strata coincide with 4 patient groups: (1) = 0: those who were admitted, never received mechanical ventilation, and were discharged, (1) = 1: those who were admitted, never received mechanical ventilation, and died, = (1) = 2: those who were admitted, received mechanical ventilation, and were discharged, and (2) = 1 | (1) = 2: those who were admitted, received mechanical ventilation, and died. We define (1) to be the date of event (1) for patient and (2) the date of event (2) conditioned on event (1) . We define the times prior to each of the events by = − (2) . The linear mixed effects models take the form: We created boxplots of standardized residuals against deciles of predicted values for each ̂ to identify systematic deviations from residual mean of 0 or changing spread among residuals that would indicate an incorrect model for the variance of the observations. We produced quantilequantile plots against the standard Gaussian distribution for the standardized residuals to assess the Gaussian assumption regarding random effects and residual errors. If we discovered a systematic deviation, we used bootstrapping to obtain robust variance estimators for the estimated population intercepts and linear slopes. From among the 1884 patients, 1445 patients were admitted and discharged without ventilation, Mean biomarker trajectories preceding patient outcomes are displayed with 95% confidence intervals in Figure 1 . The final fitted values on the day of each outcome (day 0) are presented with 95% CI in Table 3 , and the slope of values over the three days leading up to each outcome are presented in Table 4 . All likelihood ratio tests of the null hypothesis that the smoothed time trend is the same across the outcome strata were statistically significant (p<0.001). Patients discharged without ventilation had lower (better) log-CRP ( Figure 1A ), log-D-dimer ( Figure 1C ), pulse ( Figure 1I ), respiratory rate ( Figure 1K ), and temperature ( Figure 1O ) and higher (better) eGFR ( Figure 1E ), log-absolute lymphocyte count (log-ALC) ( Figure 1G ), and SpO2/FiO2 ( Figure 1M ) at discharge as compared to those who died without ventilation or were ventilated. Without ventilation, there was a divergence in log-CRP, log-ALC, respiratory rate, and SpO2/FiO2 trajectories approximately 8-10 days prior to death or discharge ( Figures 1A, 1G , 1K, and 1M). We observed a steady increase in D-dimer that began 20 days prior to death without ventilation and minimal change in D-dimer among those discharged without ventilation ( Figure 1C ). Similarly, we observed a steady increase in eGFR that began 20 days prior to discharge without ventilation and minimal change in eGFR among those who died without ventilation apart from the last few days leading up to death ( Figure 1E ). In the days leading up to ventilation, patient trajectories more closely followed trajectories of patients who died without ventilation. Among patients who required ventilation, log-CRP ( Figure 1B) , eGFR ( Figure 1F ), log-ALC ( Figure 1H ), respiratory rate ( Figure 1L ), and SpO2/FiO2 ( Figure 1N ) trajectories diverged between ventilated patients who were discharged versus died, such that values improved for those who were discharged or remained unchanged/worsened for those who died. This divergence was observed 10 or more days prior to discharge or death. Log-D-dimer and temperature diverged between ventilated patients who were discharged versus died approximately 8 days prior to discharge or death ( Figures 1D and 1P ). Almost immediately following ventilation, eGFR and SpO2/FiO2 increased among patients who were discharged compared to minimal changes among those who died ( Figures 1F and 1N Latinx and Other race/ethnicity were ventilated at higher respiratory rate. Among patients who were ventilated and discharged, those with Charlson comorbidity score >3 were discharged at lower eGFR, D-dimer, log-ALC, and pulse than those with Charlson score of 0 or 1-2 (Web The models offer patient-specific estimated curves ( Figure 2 ). Here, we plotted observed and fitted biomarker trajectories for one random patient pre-and post-ventilation. The patient's observed and fitted values overlay the population-average model-based estimates to illustrate individual variation from trajectories conditioned on outcome. For all but one of the biomarkers, the distributions of residuals were approximately Gaussian with constant variance. The respiratory rate models produced residuals such that spread increased with the mean value (Web Figure 3 ) indicating an incorrect model for the variance of estimate coefficients. We introduced robust variance estimators for the respiratory rate models and used bootstraps with 500 iterations to determine whether this improved model validity. Quantile-quantile plots of bootstrapped estimates indicated that inferences with respect to respiratory rate using robust variance were valid (Web Figure 4 ). In this study of 1884 patients with COVID-19 from one hospital system, we used a generalization of the case-control design by stratifying longitudinal data analysis into outcome- those who died. 26 We are able to provide further insight into the behavior of these inflammatory markers leading up to and following ventilation. Specifically, in our study population, CRP consistently declined over the 15 days prior to discharge following ventilation, yet remained elevated without decreasing among those who went on to die following ventilation. ALC consistently increased among patients who survived to discharge following ventilation, but increased only slightly and after some delay among those who died following ventilation. Understanding the behavior of these biomarkers independent of each other is clinically helpful as models of inflammatory states emerge. 20 In our study, patients discharged following ventilation regained SpO2/FiO2, ALC, respiratory rate, and temperatures comparable to those of patients discharged without ventilation. In contrast, these patients were discharged at lower eGFRs and higher D-dimer than those 15 discharged without ventilation. The eGFR trajectories we observed support existing evidence that COVID-19 leads to acute kidney injury in up to 25% of patients who develop critical illness. 27 This damage is likely compounded by the potential injurious impact of ventilation on kidney function. 28, 29 The D-dimer trajectories we observed are consistent with prior studies linking elevated D-dimer to an increased risk of severe disease and death. 30 We were able to further show that patients who survived to discharge but required ventilation maintained elevated D-dimer when compared to patients who were discharged without ventilation. The limitations of this study merit discussion. Our approach to modeling biomarker trajectories relevant to SARS-CoV-2 does not incorporate joint modeling of biomarkers which might provide a unified picture of health and disease trajectory for a given patient. We are bound by the restrictions of case-control design and unable to predict a given patient's trajectory, as each model requires that we know the patient's outcome. Thus, these models cannot be used for prediction, but rather provide the foundation for jointly modeling biomarker trajectories and the probability of each event. For patients on a ventilator, we modeled SpO2/FiO2 rather than PaO2/FiO2 which would allow minor changes to be better observed. SpO2/FiO2 data were reported more frequently for our study population and allowed us to compare pre-and postventilation trajectories. We chose to retrospectively characterize trajectories based on ventilation, discharge, or death, yet there is significant variation in health status and quality of life for patients within each of these outcomes, and in particular among discharged patients. We observed significant improvements in health up until discharge, yet there are unknown long-term consequences for patients discharged following COVID-19 that should be considered in the context of this work. 31 When interpreting patient trajectories, we must also recognize the Trend represents the slope of fitted values over the three days immediately preceding the event (i.e. day -3 to day 0 in in each model). For example, for patients in our study population who were admitted and discharged without requiring mechanical ventilation, log-C- Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19 (article published online ahead of print Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Patient Trajectories Among Persons Hospitalized for COVID-19 Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Case-Control Studies with Longitudinal Covariates Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review Relative Bradycardia in Patients With Septic Shock Requiring Vasopressor Therapy Characteristics and Outcomes of Individuals With Preexisting Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States Acute kidney injury in patients hospitalized with COVID-19 D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 The R Project for Statistical Computing. R Foundation for Statistical Computing Association Between Peripheral Blood Oxygen Saturation (SpO(2))/Fraction of Inspired Oxygen (FiO(2)) Ratio Time at Risk and Hospital Mortality in Mechanically Ventilated Patients Clinical Characteristics and Outcomes Are Similar in ARDS Diagnosed by Oxygen Saturation/Fio2 Ratio Compared With Pao2/Fio2 Ratio Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study Development and validation of a machine learningbased prediction model for near-term in-hospital mortality among patients with COVID-19 The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine A severity of disease classification system National early warning score (NEWS): standardising the assessment of acuteillness severity in the NHS-report of a working party C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study Acute kidney injury in critically ill patients with COVID-19 Differential effects of mechanical ventilatory strategy on lung injury and systemic organ inflammation in mice Mechanical ventilation and acute renal failure Elevated D-Dimer Levels Are Associated With Increased Risk of Mortality in Coronavirus Disease 2019: A Systematic Review and Meta-Analysis Short-and potential long-term adverse health outcomes of COVID-19: a rapid review